


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims:

1. (currently amended) A compound of the general formula (I)



wherein


R¹ is selected from hydrogen; a branched or straight C₁-C₆ alkyl; C₁-C₆ alkenyl; C₃-C₈ cycloalkyl; C₄-C₈(alkyl-cycloalkyl), wherein alkyl is C₁-C₂ alkyl and cycloalkyl is C₃-C₆ cycloalkyl; C₆-C₁₀ aryl; or heteroaryl having from 5 to 10 atoms selected from any of C, S, N and/or O; wherein the said aryl and/or heteroaryl may optionally and independently be substituted by 1 or 2 substituents independently selected from any of hydrogen, CH₃, (CH₂)_pCF₃, halogen, CONR⁵R⁴, COOR⁵, COR⁵, (CH₂)_pNR⁵R⁴, (CH₂)_pCH₃, (CH₂)_pSOR⁵R⁴, (CH₂)_pSO₂R⁵, (CH₂)_pSO₂NR⁵R⁴ and (CH₂)_pOR⁵, wherein p is 0, 1 or 2; (C₁-C₂ alkyl)-(C₆-C₁₀ aryl); or (C₁-C₂ alkyl)heteroaryl, the wherein said heteroaryl moieties having has from 5 to 10 atoms selected from any of C, S, N and/or O, and wherein the said aryl and/or heteroaryl may optionally and independently be substituted by 1 or 2 substituents independently selected from any of hydrogen, CH₃, (CH₂)_qCF₃, (CH₂)_qCF₃, halogen, -CONR⁵R⁴, -COOR⁵, -COR⁵, -(CH₂)_qNR⁵R⁴, -(CH₂)_qCH₃, (CH₂)_qSOR⁵R⁴, -(CH₂)_qSO₂R⁵, -(CH₂)_qSO₂NR⁵R⁴, and -(CH₂)_pOR⁵ -(CH₂)_qOR⁵, wherein q is 0, 1 or 2; and



R¹⁹, R²⁰, R²¹, R²², R²³, and R²⁴ is each and independently selected from hydrogen, C₁-C₆ alkyl, and or C₁-C₆ alkenyl;

R^2 and R^3 is each and independently selected from hydrogen and ~~or~~ C_1 - C_6 alkyl;

A is ~~selected from~~



~~wherein the phenyl ring of each A is substituent may be~~ optionally and independently substituted by 1 or 2 substituents Z^1 and Z^2 each and independently selected from hydrogen, CH_3 , ~~$-(CH_2)_rCF_3$~~ , $-(CH_2)_rCF_3$, halogen, $-CONR^6R^7$, $-CO_2R^6$, $-COR^6$, $-(CH_2)_rNR^6R^7$, $-(CH_2)_rCH_3$, $-(CH_2)_rSOR^6$, $-(CH_2)_rSO_2R^6$ and $-(CH_2)_rSO_2NR^6R^7$, wherein r is 0, 1, or 2;


Q is C_5 - C_6 hydroaryl; ~~or heterohydroaromatic having 5 or 6 atoms selected from any one of C, S, N and/or O; C_5 - C_6 cycloalkyl, or, or heterocycloalkyl having 5 or 6 atoms selected from any one of C, N, O and/or S; and wherein each Q may is~~ optionally be substituted by a substituent Z^1 and Z^2 as defined above;

B is ~~selected from phenyl, or naphthyl, wherein the phenyl and naphthyl is~~ optionally and independently substituted by 1 or 2 substituents ~~independently~~ selected from hydrogen, CH_3 , $-(CH_2)_tCF_3$, halogen, $-(CH_2)_tCONR^5R^4$, $-(CH_2)_tNR^5R^4$, $-(CH_2)_tCOR^5$, $-(CH_2)_tCOOR^5$, $-OR^5$, $-(CH_2)_tSOR^5$, $-(CH_2)_tSO_2R^5$, and $-(CH_2)_tSO_2NR^5R^4$, and wherein t is 0, 1, 2 or 3; and

R^4 , R^5 , R^6 , and R^7 , is each and independently selected from hydrogen; a branched or straight C_1 - C_6 alkyl; C_1 - C_6 alkenyl; C_3 - C_8 cycloalkyl; and C_4 - C_8 (alkyl-cycloalkyl), wherein alkyl is C_1 - C_2 alkyl and cycloalkyl is C_3 - C_6 cycloalkyl;

as well as pharmaceutically acceptable salts of the compounds of the formula (I), and isomers, hydrates, isoforms and prodrugs thereof.

2. (currently amended) A compound of the formula (I) according to claim 1, wherein



A is selected from Z^1 wherein the phenyl ring of each A is substituted may be optionally and independently substituted at any position of the phenyl ring by 1 or 2 substituents Z^1 and Z^2 which are is each and independently selected from hydrogen, CH_3 , $-(CH_2)_qCF_3$, $-(CH_2)_lCF_3$, halogen, $-CONR^6R^7$, $-COOR^6$, $-COR^6$, $-(CH_2)_rNR^6R^7$, $-(CH_2)_rCH_3$, $-(CH_2)_rSOR^6$, $-(CH_2)_rSO_2R^6$ and $-(CH_2)_rSO_2NR^6R^7$, wherein r is 0, 1, or 2;

Q is selected from morpholine, piperidine, or pyrrolidine;

R¹ is selected from hydrogen; a branched or straight C₁-C₄ alkyl; C₃-C₅ cycloalkyl; C₄-C₈ (alkyl-cycloalkyl), wherein alkyl is C₁-C₂ alkyl and cycloalkyl is C₃-C₆ cycloalkyl; and C₆-C₁₀ aryl; and/or heteroaryl having from 5 to 6 atoms selected from any of C, S, N and/or O; and wherein the aryl and/or heteroaryl may be optionally and independently substituted by 1 or 2 substituents independently selected from any of hydrogen, CH₃, -(CH₂)_pCF₃, halogen, -CONR⁵R⁴, -COOR⁵, -COR⁵, -(CH₂)_pNR⁵R⁴, -(CH₂)_pCH₃, -(CH₂)_pSOR⁵R⁴, -(CH₂)_pSO₂R⁵, and -(CH₂)_pSO₂NR⁵R⁴, wherein p is 0, 1 or 2;


B is selected from phenyl, and or naphthyl, wherein the phenyl and naphthyl is each optionally and independently substituted by 1 or 2 substituents independently-selected from hydrogen, CH₃, CF₃, halogen, -(CH₂)_qCONR⁵R⁴, -(CH₂)_qNR⁵R⁴, -(CH₂)_qCOR⁵, -(CH₂)_qCO₂R⁵, and -OR⁵; wherein q is 0 or 1; and wherein

R⁴, R⁵, R⁶, and R⁷, is each and independently selected from hydrogen, a branched or straight C₁-C₆ alkyl, C₁-C₆ alkenyl, C₃-C₈ cycloalkyl, and C₄-C₈(alkyl-cycloalkyl) wherein alkyl is C₁-C₂ alkyl and cycloalkyl is C₃-C₆ cycloalkyl; and

R² and R³ is each and independently selected from hydrogen or methyl.

3. (canceled)

4. (currently amended) A compound of the formula (I) according to claim 1, which compound is



wherein R is morpholine, piperidine or pyrrolidine;

5. (canceled).

6. (currently amended) A compound according to claim 1 ~~any of the preceding claims~~, in form of its hydrochloride, sulfate, tartrate or citrate salts.

7-14. (canceled)

15. (currently amended) A compound according to claim 1, wherein said compound further characterised in that it is isotopically labelled.

16. (canceled).

17. (original) An isotopically labelled compound of the formula (I) of claim 1.

18. (canceled).

19. (original) A pharmaceutical composition comprising a compound of the formula (I) according to claim 1 as an active ingredient, together with a pharmacologically and pharmaceutically acceptable carrier.

20-26. (canceled)

27. (new) A compound according to claim 4, in form of its hydrochloride, sulfate, tartrate or citrate salts.

28. (new) A pharmaceutical composition comprising a compound of the formula (I) according to claim 4 as an active ingredient, together with a pharmacologically and pharmaceutically acceptable carrier.

29. (new) A compound according to claim 2, wherein B is a phenyl substituted by 1 substituent selected from halogen.

30. (new) A compound according to claim 29, wherein the halogen is fluorine.

31. (new) A compound according to claim 30, wherein said phenyl is substituted at the meta position by said fluorine.

32.
31. (new) A compound according to claim 29, wherein Z^1 , Z^2 , and R^1 is each and independently H; and R^2 and R^3 is each and independently selected from H and CH_3 .

33.
32. (new) A compound according to claim 31, wherein Z^1 , Z^2 , R^1 , R^2 , and R^3 is each and independently H.

34.
33. (new) A compound according to claim 29, wherein Z^1 , Z^2 , R^1 , R^2 , and R^3 is each and independently H.

35.
34. (new) A compound according to claim 4, wherein said compound is isotopically labeled.

36.
35. (new) A compound according to claim 1, wherein the compound is selected from:
4-[(3-fluorophenyl)-piperidin-4-yl-methyl]-phenyl-morpholin-4-yl-methanone;
4-[(3-fluorophenyl)-piperidin-4-yl-methyl]-phenyl-piperidin-1-yl-methanone; and
4-[(3-fluorophenyl)-piperidin-4-yl-methyl]-phenyl-pyrrolidin-1-yl-methanone.